{"success":true,"data":{"pressRelease":{"id":"111093","rtpr_id":"nPn9BZn3da","ticker":"NURS","exchange":"","all_tickers":["NURS"],"title":"Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston","author":"PR Newswire","published_at":"2026-08-06T11:15:00.048Z","article_body":"Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston\n\nPR Newswire\n\nVANCOUVER, BC, Aug. 6, 2026\n\nVANCOUVER, BC, Aug. 6, 2026 /PRNewswire/ -- Hydreight Technologies Inc. (TSXV:\nNURS) (OTCQB: HYDTF) (FSE: SO6) (\"Hydreight\" or the \"Company\"), a healthcare\ntechnology company operating a nationwide physician-supervised healthcare\nplatform with a network of more than 300 licensed physicians, more than 3,000\nlicensed nurses, and pharmacy partners serving all 50 U.S. states, is pleased\nto announce that it has been invited to participate in Canaccord Genuity's\n46th Annual Growth Conference, taking place August 11–13, 2026, at the\nInterContinental Boston in Boston, Massachusetts.\n\nThe Canaccord Genuity Growth Conference is one of North America's premier\ninstitutional investor conferences, bringing together leading public and\nprivate growth companies with institutional investors from around the world\nacross the technology, healthcare & life sciences, sustainability,\nindustrials, and consumer sectors.\n\nHydreight will be represented by Shane Madden, Chief Executive Officer, and\nShafin Diamond Tejani, Board Chair, who will meet with institutional investors\nthroughout the conference to discuss the Company's recent operating progress,\nexpanding healthcare ecosystem, and long-term growth strategy.\n\n\"We're pleased to once again participate in the Canaccord Genuity Growth\nConference and share Hydreight's continued progress with the investment\ncommunity,\" said Shane Madden, Chief Executive Officer of Hydreight. \"Over the\npast year, we have continued executing on our strategy by expanding the\nVSDHOne ecosystem, growing our nationwide healthcare infrastructure,\nbroadening our portfolio of physician-supervised healthcare programs, and\ndelivering strong financial performance. We look forward to meeting with\ninvestors and discussing the opportunities we see ahead.\"\nRecent Corporate Highlights\n * Reported record first quarter 2026 revenue\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4746607-1&h=1415755361&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fhydreight-delivers-record-first-quarter-2026-revenue-of-24-9-million-with-449-revenue-growth-3-3-million-in-adjusted-ebitda-and-32-0-million-in-working-capital-302787780.html&a=Reported+record+first+quarter+2026+revenue)\n\n of $24.9 million, representing 449% year-over-year growth, Adjusted EBITDA\nof $3.3 million and $32 million in working capital.\n * Expanded the VSDHOne ecosystem to more than 12,000 licenses sold, compared to\napproximately 3,000 licenses at the end of 2025.\n * Expanded its nationwide healthcare network to include more than 300 licensed\nphysicians, more than 3,000 licensed nurses, nationwide pharmacy partnerships,\nand operations across all 50 U.S. states.\n * Expanded its portfolio to more than 45 physician-supervised healthcare\nproducts and programs, including GLP-1s, peptides, hormone health, weight\nmanagement, wellness, diagnostics, and preventative healthcare offerings.\n * Recently provided a business update outlining\n the Company's peptide healthcare platform\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4746607-1&h=1773019247&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fhydreight-provides-business-update-on-its-peptide-healthcare-platform-following-recent-fda-advisory-committee-recommendations-302837420.html&a=%C2%A0the+Company%27s+peptide+healthcare+platform)\n\n following the U.S. Food and Drug Administration's recent advisory committee\nrecommendations related to certain compounded peptide substances.\n * Maintained a strong cash position to support continued organic growth,\nplatform expansion, and strategic opportunities.\nManagement expects discussions with investors to focus on the Company's\ncontinued operating momentum, expansion of the VSDHOne platform, peptide\nhealthcare initiatives, and long-term growth strategy.\n\nThe Company encourages institutional investors interested in meeting with\nmanagement during the conference to contact their Canaccord Genuity\nrepresentative.\n\nOn behalf of the Board of Directors\n\nShane Madden\nDirector and Chief Executive Officer\nHydreight Technologies Inc.\n\nAbout Hydreight Technologies Inc.\n\nHydreight Technologies Inc. is building a nationwide physician-supervised\nhealthcare platform across the United States. Its proprietary technology\nplatform supports a network of more than 300 licensed physicians, more than\n3,000 licensed nurses, and a nationwide pharmacy network serving all 50 U.S.\nstates. The platform includes integrated telehealth, compliance, medical\ndocumentation, scheduling, pharmacy, billing, and patient engagement tools\nthat enable licensed healthcare professionals and healthcare brands to deliver\ncompliant healthcare services across the country. Through its infrastructure\nand VSDHOne platform, Hydreight enables businesses to launch and scale\ncompliant direct-to-consumer healthcare brands while expanding patient access\nto physician-supervised care.\n\nAbout VSDHOne\n\nDeveloped in partnership with Victory Square Technologies (CSE: VST) (OTCQX:\nVSQTF) (FWB: 6F6), VSDHOne is Hydreight's direct-to-consumer healthcare\nplatform that enables businesses to launch compliant virtual healthcare brands\nacross all 50 U.S. states. The platform provides an end-to-end solution\nincluding telehealth technology, compliance infrastructure, physician\noversight, pharmacy fulfillment, payment processing, and patient support.\nThrough VSDHOne, businesses can offer physician-supervised healthcare programs\nincluding GLP-1s, peptides, hormone replacement therapy (HRT), testosterone\nreplacement therapy (TRT), weight management, hair loss, skincare, sexual\nhealth, longevity, IV wellness, diagnostics, and other personalized healthcare\nofferings.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nUse of Non-GAAP Financial Measures:\n\nThe Company uses certain non-GAAP financial measures to assess its operating\nperformance, and this press release contains non-GAAP financial measures,\nincluding \"Adjusted Revenue\" and \"Adjusted EBITDA\". These measures are not\nrecognized under International Financial Reporting Standards (\"IFRS\") and do\nnot have standardized meanings prescribed by IFRS or GAAP.\n\nThe Company defines Adjusted Revenue as gross cash income before adjustment\nfor the deferred portion of business partner contract revenue and gross\nreceipts from Hydreight App service sales. The Company defines Adjusted Gross\nMargin as GAAP gross margin plus inventory impairment plus the deferred\nportion of business partner contract revenue. The Company defines Adjusted\nEBITDA as net income (loss) before interest, taxes, depreciation and\namortization and before (i) transaction, restructuring, and integration costs\n(ii) share-based payments expense, (iii) gains/losses that are not reflective\nof ongoing operating performance including inventory impairment and (iv) sales\ntax provision, net of actual cash payments to state tax authorities.\n\nAdjusted Revenue reflects the gross economic activity processed through the\nCompany's platform during the applicable period and may differ materially from\nrevenue recognized under IFRS, which is based on revenue recognition and\ndeferral requirements. Adjusted Revenue is not a measure of financial\nperformance or profitability and should not be considered a substitute for\nrevenue determined in accordance with IFRS.  As used, Adjusted Revenue\naccelerates cash receipts relative to IFRS revenue recognition. Adjusted\nEBITDA should not be considered in isolation or as a substitute for net income\n(loss) prepared in accordance with IFRS.\n\nThe Company believes that these non‑GAAP measures provide information useful\nto investors in understanding historical operating trends and the scale of the\nCompany's platform relative to its peers but does not intend for such measures\nto represent future performance. This data is furnished to provide additional\ninformation and does not have any standardized meaning prescribed by IFRS.\nAccordingly, it should not be considered in isolation or as a substitute for\nmeasures of performance prepared in accordance with IFRS and is not\nnecessarily indicative of other metrics presented in accordance with IFRS.\n\nCautionary Note Regarding Forward-Looking Information\n\nThis press release contains statements which constitute \"forward-looking\ninformation\" within the meaning of applicable securities laws, including\nstatements regarding the plans, intentions, beliefs and current expectations\nof the Company with respect to future business activities and operating\nperformance. Forward-looking information is often identified by the words\n\"may\", \"would\", \"could\", \"should\", \"will\", \"intend\", \"plan\", \"anticipate\",\n\"believe\", \"estimate\", \"expect\" or similar expressions and includes\ninformation regarding expectations for the Company's 2026 strategic outlook,\ngrowth, platform scaling initiatives, and anticipated expansion of VSDHOne and\nother platform offerings.\n\nForward‑looking information is based on management's expectations, estimates\nand assumptions as of the date hereof, including assumptions regarding:\ncontinued partner adoption, stable regulatory regimes applicable to telehealth\nand pharmacy operations in the United States, availability of capital, and\ngeneral economic conditions.\nInvestors are cautioned that forward-looking information is not based on\nhistorical facts but instead reflects the Company's management's expectations,\nestimates or projections concerning future results or events based on the\nopinions, assumptions and estimates of management considered reasonable at the\ndate the statements are made. Although the Company believes that the\nexpectations reflected in such forward-looking information are reasonable,\nsuch information involves risks and uncertainties, and undue reliance should\nnot be placed on such information, as unknown or unpredictable factors could\nhave material adverse effects on future results, performance or achievements\nof the Company.\n\nAmong the key factors that could cause actual results to differ materially\nfrom those projected in the forward-looking information are the following: the\nability to obtain requisite regulatory and other approvals with respect to the\nbusiness operated by the Company and/or the potential impact of the listing of\nthe Company's shares on the TSXV on relationships, including with regulatory\nbodies, employees, suppliers, customers and competitors; changes in general\neconomic, business and political conditions, including changes in the\nfinancial markets; changes in applicable laws; compliance with extensive\ngovernment regulation; and the diversion of management time as a result of\nbeing a publicly listed entity. This forward-looking information may be\naffected by risks and uncertainties in the business of the Company and market\nconditions.\n\nShould one or more of these risks or uncertainties materialize, or should\nassumptions underlying the forward-looking information prove incorrect, actual\nresults may vary materially from those described herein as intended, planned,\nanticipated, believed, estimated or expected. Although the Company has\nattempted to identify important risks, uncertainties and factors which could\ncause actual results to differ materially, there may be others that cause\nresults not to be as anticipated, estimated or intended. The Company does not\nintend, and does not assume any obligation, to update this forward-looking\ninformation except as otherwise required by applicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/hydreight-to-participate-in-canaccord-genuitys-46th-annual-growth-conference-in-boston-302844055.html\n(https://www.prnewswire.com/news-releases/hydreight-to-participate-in-canaccord-genuitys-46th-annual-growth-conference-in-boston-302844055.html)\n\nSOURCE Hydreight Technologies Inc.\n\n\n\nEmail: ir@hydreight.com, Telephone: 1 (702) 970-8112\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1802513/Hydreight-Technologies-Inc-Hydreight-to-Participate-in-Canaccor.jpg?id=OA2827302\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9BZn3da","title":"Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston","author":"PR Newswire","ticker":"NURS","created":"2026-08-06T11:15:00.048Z","tickers":["NURS"],"exchange":"","article_body":"Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston\n\nPR Newswire\n\nVANCOUVER, BC, Aug. 6, 2026\n\nVANCOUVER, BC, Aug. 6, 2026 /PRNewswire/ -- Hydreight Technologies Inc. (TSXV:\nNURS) (OTCQB: HYDTF) (FSE: SO6) (\"Hydreight\" or the \"Company\"), a healthcare\ntechnology company operating a nationwide physician-supervised healthcare\nplatform with a network of more than 300 licensed physicians, more than 3,000\nlicensed nurses, and pharmacy partners serving all 50 U.S. states, is pleased\nto announce that it has been invited to participate in Canaccord Genuity's\n46th Annual Growth Conference, taking place August 11–13, 2026, at the\nInterContinental Boston in Boston, Massachusetts.\n\nThe Canaccord Genuity Growth Conference is one of North America's premier\ninstitutional investor conferences, bringing together leading public and\nprivate growth companies with institutional investors from around the world\nacross the technology, healthcare & life sciences, sustainability,\nindustrials, and consumer sectors.\n\nHydreight will be represented by Shane Madden, Chief Executive Officer, and\nShafin Diamond Tejani, Board Chair, who will meet with institutional investors\nthroughout the conference to discuss the Company's recent operating progress,\nexpanding healthcare ecosystem, and long-term growth strategy.\n\n\"We're pleased to once again participate in the Canaccord Genuity Growth\nConference and share Hydreight's continued progress with the investment\ncommunity,\" said Shane Madden, Chief Executive Officer of Hydreight. \"Over the\npast year, we have continued executing on our strategy by expanding the\nVSDHOne ecosystem, growing our nationwide healthcare infrastructure,\nbroadening our portfolio of physician-supervised healthcare programs, and\ndelivering strong financial performance. We look forward to meeting with\ninvestors and discussing the opportunities we see ahead.\"\nRecent Corporate Highlights\n * Reported record first quarter 2026 revenue\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4746607-1&h=1415755361&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fhydreight-delivers-record-first-quarter-2026-revenue-of-24-9-million-with-449-revenue-growth-3-3-million-in-adjusted-ebitda-and-32-0-million-in-working-capital-302787780.html&a=Reported+record+first+quarter+2026+revenue)\n\n of $24.9 million, representing 449% year-over-year growth, Adjusted EBITDA\nof $3.3 million and $32 million in working capital.\n * Expanded the VSDHOne ecosystem to more than 12,000 licenses sold, compared to\napproximately 3,000 licenses at the end of 2025.\n * Expanded its nationwide healthcare network to include more than 300 licensed\nphysicians, more than 3,000 licensed nurses, nationwide pharmacy partnerships,\nand operations across all 50 U.S. states.\n * Expanded its portfolio to more than 45 physician-supervised healthcare\nproducts and programs, including GLP-1s, peptides, hormone health, weight\nmanagement, wellness, diagnostics, and preventative healthcare offerings.\n * Recently provided a business update outlining\n the Company's peptide healthcare platform\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4746607-1&h=1773019247&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fhydreight-provides-business-update-on-its-peptide-healthcare-platform-following-recent-fda-advisory-committee-recommendations-302837420.html&a=%C2%A0the+Company%27s+peptide+healthcare+platform)\n\n following the U.S. Food and Drug Administration's recent advisory committee\nrecommendations related to certain compounded peptide substances.\n * Maintained a strong cash position to support continued organic growth,\nplatform expansion, and strategic opportunities.\nManagement expects discussions with investors to focus on the Company's\ncontinued operating momentum, expansion of the VSDHOne platform, peptide\nhealthcare initiatives, and long-term growth strategy.\n\nThe Company encourages institutional investors interested in meeting with\nmanagement during the conference to contact their Canaccord Genuity\nrepresentative.\n\nOn behalf of the Board of Directors\n\nShane Madden\nDirector and Chief Executive Officer\nHydreight Technologies Inc.\n\nAbout Hydreight Technologies Inc.\n\nHydreight Technologies Inc. is building a nationwide physician-supervised\nhealthcare platform across the United States. Its proprietary technology\nplatform supports a network of more than 300 licensed physicians, more than\n3,000 licensed nurses, and a nationwide pharmacy network serving all 50 U.S.\nstates. The platform includes integrated telehealth, compliance, medical\ndocumentation, scheduling, pharmacy, billing, and patient engagement tools\nthat enable licensed healthcare professionals and healthcare brands to deliver\ncompliant healthcare services across the country. Through its infrastructure\nand VSDHOne platform, Hydreight enables businesses to launch and scale\ncompliant direct-to-consumer healthcare brands while expanding patient access\nto physician-supervised care.\n\nAbout VSDHOne\n\nDeveloped in partnership with Victory Square Technologies (CSE: VST) (OTCQX:\nVSQTF) (FWB: 6F6), VSDHOne is Hydreight's direct-to-consumer healthcare\nplatform that enables businesses to launch compliant virtual healthcare brands\nacross all 50 U.S. states. The platform provides an end-to-end solution\nincluding telehealth technology, compliance infrastructure, physician\noversight, pharmacy fulfillment, payment processing, and patient support.\nThrough VSDHOne, businesses can offer physician-supervised healthcare programs\nincluding GLP-1s, peptides, hormone replacement therapy (HRT), testosterone\nreplacement therapy (TRT), weight management, hair loss, skincare, sexual\nhealth, longevity, IV wellness, diagnostics, and other personalized healthcare\nofferings.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nUse of Non-GAAP Financial Measures:\n\nThe Company uses certain non-GAAP financial measures to assess its operating\nperformance, and this press release contains non-GAAP financial measures,\nincluding \"Adjusted Revenue\" and \"Adjusted EBITDA\". These measures are not\nrecognized under International Financial Reporting Standards (\"IFRS\") and do\nnot have standardized meanings prescribed by IFRS or GAAP.\n\nThe Company defines Adjusted Revenue as gross cash income before adjustment\nfor the deferred portion of business partner contract revenue and gross\nreceipts from Hydreight App service sales. The Company defines Adjusted Gross\nMargin as GAAP gross margin plus inventory impairment plus the deferred\nportion of business partner contract revenue. The Company defines Adjusted\nEBITDA as net income (loss) before interest, taxes, depreciation and\namortization and before (i) transaction, restructuring, and integration costs\n(ii) share-based payments expense, (iii) gains/losses that are not reflective\nof ongoing operating performance including inventory impairment and (iv) sales\ntax provision, net of actual cash payments to state tax authorities.\n\nAdjusted Revenue reflects the gross economic activity processed through the\nCompany's platform during the applicable period and may differ materially from\nrevenue recognized under IFRS, which is based on revenue recognition and\ndeferral requirements. Adjusted Revenue is not a measure of financial\nperformance or profitability and should not be considered a substitute for\nrevenue determined in accordance with IFRS.  As used, Adjusted Revenue\naccelerates cash receipts relative to IFRS revenue recognition. Adjusted\nEBITDA should not be considered in isolation or as a substitute for net income\n(loss) prepared in accordance with IFRS.\n\nThe Company believes that these non‑GAAP measures provide information useful\nto investors in understanding historical operating trends and the scale of the\nCompany's platform relative to its peers but does not intend for such measures\nto represent future performance. This data is furnished to provide additional\ninformation and does not have any standardized meaning prescribed by IFRS.\nAccordingly, it should not be considered in isolation or as a substitute for\nmeasures of performance prepared in accordance with IFRS and is not\nnecessarily indicative of other metrics presented in accordance with IFRS.\n\nCautionary Note Regarding Forward-Looking Information\n\nThis press release contains statements which constitute \"forward-looking\ninformation\" within the meaning of applicable securities laws, including\nstatements regarding the plans, intentions, beliefs and current expectations\nof the Company with respect to future business activities and operating\nperformance. Forward-looking information is often identified by the words\n\"may\", \"would\", \"could\", \"should\", \"will\", \"intend\", \"plan\", \"anticipate\",\n\"believe\", \"estimate\", \"expect\" or similar expressions and includes\ninformation regarding expectations for the Company's 2026 strategic outlook,\ngrowth, platform scaling initiatives, and anticipated expansion of VSDHOne and\nother platform offerings.\n\nForward‑looking information is based on management's expectations, estimates\nand assumptions as of the date hereof, including assumptions regarding:\ncontinued partner adoption, stable regulatory regimes applicable to telehealth\nand pharmacy operations in the United States, availability of capital, and\ngeneral economic conditions.\nInvestors are cautioned that forward-looking information is not based on\nhistorical facts but instead reflects the Company's management's expectations,\nestimates or projections concerning future results or events based on the\nopinions, assumptions and estimates of management considered reasonable at the\ndate the statements are made. Although the Company believes that the\nexpectations reflected in such forward-looking information are reasonable,\nsuch information involves risks and uncertainties, and undue reliance should\nnot be placed on such information, as unknown or unpredictable factors could\nhave material adverse effects on future results, performance or achievements\nof the Company.\n\nAmong the key factors that could cause actual results to differ materially\nfrom those projected in the forward-looking information are the following: the\nability to obtain requisite regulatory and other approvals with respect to the\nbusiness operated by the Company and/or the potential impact of the listing of\nthe Company's shares on the TSXV on relationships, including with regulatory\nbodies, employees, suppliers, customers and competitors; changes in general\neconomic, business and political conditions, including changes in the\nfinancial markets; changes in applicable laws; compliance with extensive\ngovernment regulation; and the diversion of management time as a result of\nbeing a publicly listed entity. This forward-looking information may be\naffected by risks and uncertainties in the business of the Company and market\nconditions.\n\nShould one or more of these risks or uncertainties materialize, or should\nassumptions underlying the forward-looking information prove incorrect, actual\nresults may vary materially from those described herein as intended, planned,\nanticipated, believed, estimated or expected. Although the Company has\nattempted to identify important risks, uncertainties and factors which could\ncause actual results to differ materially, there may be others that cause\nresults not to be as anticipated, estimated or intended. The Company does not\nintend, and does not assume any obligation, to update this forward-looking\ninformation except as otherwise required by applicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/hydreight-to-participate-in-canaccord-genuitys-46th-annual-growth-conference-in-boston-302844055.html\n(https://www.prnewswire.com/news-releases/hydreight-to-participate-in-canaccord-genuitys-46th-annual-growth-conference-in-boston-302844055.html)\n\nSOURCE Hydreight Technologies Inc.\n\n\n\nEmail: ir@hydreight.com, Telephone: 1 (702) 970-8112\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1802513/Hydreight-Technologies-Inc-Hydreight-to-Participate-in-Canaccor.jpg?id=OA2827302\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-06T11:15:00.105608142Z","server_sent_at_ms":1786014900105},"received_at":"2026-08-06T11:15:00.165Z","source_url":"https://www.prnewswire.com/news-releases/hydreight-to-participate-in-canaccord-genuitys-46th-annual-growth-conference-in-boston-302844055.html"},"analysis":{"id":"100097","press_release_id":"111093","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Hydreight Technologies announced that CEO Shane Madden and Board Chair Shafin Diamond Tejani will attend the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11–13.\n\nThe company highlighted record Q1 2026 revenue of $24.9 million, representing 449% year-over-year growth, alongside $3.3 million in adjusted EBITDA.\n\nOperational milestones include expanding the VSDHOne ecosystem to over 12,000 licenses and growing the network to more than 300 physicians and 3,000 nurses across all 50 U.S. states.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation with strong historical growth recap."},"keyFigures":{"revenue":24900000,"revenueYoy":"449%","customDimensions":{"adjusted_ebitda":3300000,"licensed_nurses":3000,"working_capital":32000000,"vsdhone_licenses":12000,"healthcare_programs":45,"licensed_physicians":300}},"quotedText":"We're pleased to once again participate in the Canaccord Genuity Growth Conference and share Hydreight's continued progress with the investment community","namedEntities":{"people":[{"name":"Shane Madden","role":"Chief Executive Officer"},{"name":"Shafin Diamond Tejani","role":"Board Chair"}],"products":["VSDHOne"],"companies":[{"name":"Hydreight Technologies Inc.","ticker":"NURS"},{"name":"Canaccord Genuity","relationship":"conference host"},{"name":"Victory Square Technologies","ticker":"VST","relationship":"partner"}],"dollarAmounts":[{"amount":"$24.9 million","context":"Q1 2026 revenue"},{"amount":"$3.3 million","context":"Adjusted EBITDA"},{"amount":"$32 million","context":"working capital"}]},"materialImpact":{"score":2,"reasoning":"Routine conference participation announcement; while the release highlights strong historical growth metrics, the event itself is non-material and routine."},"tickerRelevance":{"others":[{"ticker":"VST","relevance":"partner"},{"ticker":"VSQTF","relevance":"partner"},{"ticker":"6F6","relevance":"partner"}],"primary":"NURS"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-announcement"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Hydreight Technologies announced that CEO Shane Madden and Board Chair Shafin Diamond Tejani will attend the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11–13.\n\nThe company highlighted record Q1 2026 revenue of $24.9 million, representing 449% year-over-year growth, alongside $3.3 million in adjusted EBITDA.\n\nOperational milestones include expanding the VSDHOne ecosystem to over 12,000 licenses and growing the network to more than 300 physicians and 3,000 nurses across all 50 U.S. states.","key_figures":{"revenue":24900000,"revenueYoy":"449%","customDimensions":{"adjusted_ebitda":3300000,"licensed_nurses":3000,"working_capital":32000000,"vsdhone_licenses":12000,"healthcare_programs":45,"licensed_physicians":300}},"named_entities":{"people":[{"name":"Shane Madden","role":"Chief Executive Officer"},{"name":"Shafin Diamond Tejani","role":"Board Chair"}],"products":["VSDHOne"],"companies":[{"name":"Hydreight Technologies Inc.","ticker":"NURS"},{"name":"Canaccord Genuity","relationship":"conference host"},{"name":"Victory Square Technologies","ticker":"VST","relationship":"partner"}],"dollarAmounts":[{"amount":"$24.9 million","context":"Q1 2026 revenue"},{"amount":"$3.3 million","context":"Adjusted EBITDA"},{"amount":"$32 million","context":"working capital"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-06T17:00:57.077Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-announcement"}},"durationMs":167674,"modelName":"glm-4.7"}}